US74754R2022 - Common Stock
JUPITER, FL - (NewMediaWire) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a...
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient...
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE...
Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept....
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on...
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business...
Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in...
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on...
Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) --...
CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences...
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) --...
CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE...
The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning!
CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
Data demonstrates potential anti-RAS activity with Qualigen’s novel RAS small molecule in both pancreatic and breast cancer in vivo models CARLSBAD,...
S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) --...
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...